BioNTech SE (22UA.F)
EUR 86.05
(1.24%)
EUR 86.05
(1.24%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -11.44 Billion EUR | 16.24% |
| 2022 | -13.66 Billion EUR | -882.09% |
| 2021 | -1.39 Billion EUR | -43.42% |
| 2020 | -970.02 Million EUR | -115.44% |
| 2019 | -450.24 Million EUR | -26.02% |
| 2018 | -357.27 Million EUR | -193.43% |
| 2017 | -121.75 Million EUR | 56.05% |
| 2016 | -277.01 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -8.74 Billion EUR | 23.56% |
| 2024 Q2 | -10.12 Billion EUR | -15.77% |
| 2023 Q3 | -13.29 Billion EUR | 4.78% |
| 2023 FY | -11.44 Billion EUR | 16.24% |
| 2023 Q2 | -13.96 Billion EUR | -16.98% |
| 2023 Q1 | -11.93 Billion EUR | 12.65% |
| 2023 Q4 | -11.44 Billion EUR | 13.91% |
| 2022 Q4 | -13.66 Billion EUR | -3.9% |
| 2022 FY | -13.66 Billion EUR | -882.09% |
| 2022 Q3 | -13.14 Billion EUR | -44.57% |
| 2022 Q2 | -9.09 Billion EUR | -52.15% |
| 2022 Q1 | -5.97 Billion EUR | -329.71% |
| 2021 Q4 | -1.39 Billion EUR | 33.94% |
| 2021 Q1 | -636.9 Million EUR | 46.97% |
| 2021 Q3 | -2.1 Billion EUR | -220.4% |
| 2021 Q2 | -657.3 Million EUR | -3.2% |
| 2021 FY | -1.39 Billion EUR | -43.42% |
| 2020 Q3 | -814.84 Million EUR | -62.09% |
| 2020 Q1 | -384.95 Million EUR | 14.5% |
| 2020 FY | -970.02 Million EUR | -115.44% |
| 2020 Q4 | -1.2 Billion EUR | -47.4% |
| 2020 Q2 | -502.72 Million EUR | -30.59% |
| 2019 Q1 | 411.83 Million EUR | 215.27% |
| 2019 FY | -450.24 Million EUR | -26.02% |
| 2019 Q4 | -450.24 Million EUR | -13.84% |
| 2019 Q2 | -223.55 Million EUR | -154.28% |
| 2019 Q3 | -395.49 Million EUR | -76.91% |
| 2018 FY | -357.27 Million EUR | -193.43% |
| 2018 Q4 | -357.27 Million EUR | 0.0% |
| 2018 Q1 | 172.35 Million EUR | 0.0% |
| 2017 FY | -121.75 Million EUR | 56.05% |
| 2016 FY | -277.01 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| CureVac N.V. | -360.92 Million EUR | -3070.905% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 2103.256% |
| Biotest Aktiengesellschaft | 571.3 Million EUR | 2103.256% |
| BRAIN Biotech AG | -693 Thousand EUR | -1651357.431% |
| Formycon AG | 2.45 Million EUR | 467035.945% |
| Heidelberg Pharma AG | -37.6 Million EUR | -30331.66% |
| Medigene AG | -5.72 Million EUR | -199840.601% |